Core Viewpoint - The stock of Baiaosaitu-B (02135) has seen a significant increase of over 7% in the afternoon trading session, attributed to recent licensing agreements with Tubulis and Merck, highlighting the company's competitive edge in the antibody development sector [1] Group 1: Licensing Agreements - On September 16, Baiaosaitu announced a licensing agreement with German ADC developer Tubulis, utilizing its proprietary RenMice fully human antibody development platform for innovative ADC therapies [1] - Under the agreement with Tubulis, Baiaosaitu will receive an upfront payment, milestone payments related to development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - Earlier, on September 4, Baiaosaitu signed an antibody option and evaluation agreement with Merck, focusing on evaluating antibodies developed from the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Performance - As of the report, Baiaosaitu's stock price is at 26.58 HKD, with a trading volume of 16.7354 million HKD, reflecting a 4.07% increase at the time of publication [1] - The recent agreements with Tubulis and Merck underscore the international competitiveness and drug conversion potential of Baiaosaitu's fully human antibody platform, as stated by the company's Chairman and CEO, Shen Yulei [1]

Core Viewpoint - 百奥赛图-B has signed a licensing agreement with German ADC developer Tubulis to utilize its RenMice fully human antibody development platform for innovative ADC therapies, indicating strong international competitiveness and drug conversion potential [1] Group 1: Company Developments - 百奥赛图-B's stock rose over 7% in the afternoon trading session, with a current price of 26.58 HKD and a trading volume of 16.7354 million HKD [1] - The agreement with Tubulis includes an upfront payment, milestone payments for development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - On September 4, 百奥赛图-B signed an antibody option and evaluation agreement with Merck to assess antibodies developed using the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Implications - The agreements with Tubulis and Merck highlight the international competitiveness of 百奥赛图-B's fully human antibody platform and its potential for drug conversion [1]

Core Viewpoint - The company BaiO Saite-B (02135) has signed a licensing agreement with German ADC developer Tubulis, leveraging its RenMice fully human antibody development platform for innovative ADC therapies, which is expected to enhance its market position and revenue potential [1] Group 1: Licensing Agreement with Tubulis - On September 16, BaiO Saite announced a licensing agreement with Tubulis to utilize its RenMice platform for developing ADC therapies, which includes an upfront payment and milestone payments based on development, regulatory, and commercialization achievements, along with a single-digit percentage of net sales [1] - The stock price of BaiO Saite increased by over 7% in the afternoon trading session, reflecting positive market sentiment regarding the agreement [1] Group 2: Previous Agreement with Merck - On September 4, BaiO Saite signed an antibody option and evaluation agreement with Merck to assess the fully human antibodies developed using the RenMice platform for potential applications in nucleic acid drug delivery [1] - The agreements with Tubulis and Merck highlight the international competitiveness and drug conversion potential of BaiO Saite's fully human antibody platform, as stated by the company's Chairman and CEO Shen Yuelai [1]